Sweroside attenuates podocyte injury and proteinuria in part by activating Akt/BAD signaling in mice
Journal of Cellular Biochemistry · 2023
DOI: 10.1002/jcb.30484 ↗At a glance
Journal article in Journal of Cellular Biochemistry, 2023. Written by Minjiang Huang and 10 co-authors. Institution: Department of Diagnostics, Hunan University of Medicine, Huaihua, Hunan, China. Major MEDLINE topics: Podocytes, Diabetes Mellitus, Experimental, Diabetic Nephropathies. Cited 6 times so far (Crossref); 37 references. Funded by: Science and Technology Plan Project of Huaihua, Hunan Provincial Natural Science Foundation of China, Scientific Research Fund of Hunan Provincial Education Department.
Abstract (original language)
In this study, we investigated the effects of sweroside on podocyte injury in diabetic nephropathy (DN) mice and elucidated its molecular mechanisms. We conducted in vivo experiments using a C57BL/6 mice model of DN to explore the effects of sweroside on proteinuria and podocyte injury in DN mice. In in vitro experiments, conditionally immortalized mouse podocytes were treated with high glucose and sweroside, and the protective effects of sweroside on podocyte injury were analyzed. In vitro, Akt/BAD pathways were detected using gene siRNA silencing assays and found to be involved in the protective roles of sweroside in high glucose‐mediated podocyte injury. In vivo, sweroside significantly decreased albuminuria in DN mice ( p < 0.01). periodic acid‐Schiff staining showed that sweroside alleviated the glomerular volume and mesangium expansion in DN mice. Consistently, western blot and reverse transcription‐polymerase chain reaction analyses showed that the profibrotic molecule expression in the glomeruli declined in sweroside‐treated DN mice. Immunofluorescent results showed that sweroside preserved nephrin and podocin expression, and transmission electron microscopy showed that sweroside attenuated podocyte injury. In DN mice, sweroside decreased podocyte apoptosis, and increased nephrin, podocin expression and decreased desmin and HIF1α expression. These results confirmed that sweroside ameliorated albuminuria, glomerulomegaly, and glomerulosclerosis in these mice. Experiments in vitro revealed that sweroside improved HG‐induced podocyte injury and apoptosis. Sweroside stimulated activation of the Akt/BAD pathway and upregulated Bcl‐2‐associated death promoter (BAD) and p‐Akt. Overall, sweroside protected podocytes from injury and prevented the progression of DN, providing a novel strategy for the treatment of DN.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Diagnostics, Hunan University of Medicine, Huaihua, Hunan, China.
- School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua, Hunan, China.
- Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Hunan University of Medicine, Huaihua, China.
ORCID profiles: Yan Ding
Funding
- Science and Technology Plan Project of Huaihua
- Hunan Provincial Natural Science Foundation of China
- Scientific Research Fund of Hunan Provincial Education Department
- Doctoral Scientific Research Foundation of Hunan University of Medicine
Cite
APA
Huang, M., Yang, Y., Chen, Y., Li, Y., Qin, S., Xiao, L., Long, X., Hu, K., Li, Y., Ying, H., & Ding, Y. (2023). Sweroside attenuates podocyte injury and proteinuria in part by activating Akt/BAD signaling in mice. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30484
Vancouver
Huang M, Yang Y, Chen Y, Li Y, Qin S, Xiao L, et al. Sweroside attenuates podocyte injury and proteinuria in part by activating Akt/BAD signaling in mice. Journal of Cellular Biochemistry. 2023. doi:10.1002/jcb.30484
BibTeX
@article{Huang2023,
author = {Huang, Minjiang and Yang, Yang and Chen, Yuefu and Li, Yang and Qin, Sitao and Xiao, Lijun and Long, Xuewen and Hu, Ke and Li, Yuxian and Ying, Huiming and Ding, Yan},
title = {Sweroside attenuates podocyte injury and proteinuria in part by activating Akt/BAD signaling in mice},
journal = {Journal of Cellular Biochemistry},
year = {2023},
doi = {10.1002/jcb.30484}
}
EUVIMED